Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of river blindness?

Clinical Infectious Diseases

Volumn 62, Issue 11, 2016, Pages 1338-1347

  Frempong, Kwadwo K ^a   Walker, Martin ^b   Cheke, Robert A ^b,c   Tetevi, Edward Jenner ^d   Gyan, Ernest Tawiah ^d   Owusu, Ebenezer O ^e   Wilson, Michael D ^a   Boakye, Daniel A ^a   Taylor, Mark J ^f   Biritwum, Nana Kwadwo ^g   Osei Atweneboana, Mike ^d   Basáñez, María Gloria ^b  

^a University of Ghana   (Ghana)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GREENWICH   (United Kingdom)

^d CSIR WATER RESEARCH INSTITUTE   (Ghana)

^e UNIVERSITY OF GHANA   (Ghana)

^f LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^g GHANA HEALTH SERVICE   (Ghana)

Author keywords

biannual treatment; elimination; ivermectin; onchocerciasis; suboptimal responses

Indexed keywords

IVERMECTIN; ANTIPARASITIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ELIMINATION; GHANA; HUMAN; INFECTION CONTROL; MICROFILARIA; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; MALE; ONCHOCERCIASIS, OCULAR; PARASITE LOAD; PARASITOLOGY; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPARASITIC AGENTS; COHORT STUDIES; GHANA; HUMANS; IVERMECTIN; MALE; ONCHOCERCIASIS, OCULAR; PARASITE LOAD; PREVALENCE; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84971556299     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw144     Document Type: Article

References (40)

1. Crump A, O'mura S. Ivermectin, wonder drug from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87:13-28.
2. Alley ES, Plaisier AP, Boatin BA, et al. The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Trans R Soc Trop Med Hyg 1994; 88:581-4.
3. Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and metaanalysis. Lancet Infect Dis 2008; 8:310-22.
4. Brattig NW. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect 2004; 6:113-28.
5. Plaisier AP, van Oortmarssen GJ, Remme J, Habbema JDF. The reproductive lifespan of Onchocerca volvulus inWest African savanna. Acta Trop 1991; 48:271-84.
6. Traore MO, Sarr MD, Badji A, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis 2012; 6:1371.
7. Tekle AH, Elhassan E, Isiyaku S, et al. Impact of long-Term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors 2012; 5:28.
8. Rodríguez-Pérez MA, Fernández-Santos NA, Orozco-Algarra ME, et al. Elimination of onchocerciasis from Mexico. PLoS Negl Trop Dis 2015; 9:e0003922.
9. West S, Munoz B, Sommer A. River blindness eliminated in Colombia. Ophthalmic Epidemiol 2013; 20:258-9.
10. Lovato R, Guevara A, Guderian R, et al. Interruption of infection transmission in the onchocerciasis focus of Ecuador leading to the cessation of ivermectin distribution. PLoS Negl Trop Dis 2014; 8:e2821.
11. Convit J, Schuler H, Borges R, et al. Interruption of Onchocerca volvulus transmission in northern Venezuela. Parasit Vectors 2013; 6:289.
12. Katabarwa M, Richards F. Twice-yearly ivermectin for onchocerciasis: the time is now. Lancet Infect Dis 2014; 14:373-4.
13. Katabarwa M, Lakwo T, Habomugisha P, et al. Transmission of Onchocerca volvulus by Simulium neavei in Mount Elgon focus of eastern Uganda has been interrupted. Am J Trop Med Hyg 2014; 90:1159-66.
14. African Programme for Onchocerciasis Control (APOC). Report of the thirtyeighth session of the technical consultative committee. Available at: http://www. who.int/apoc/about/structure/tcc/tcc38-final-report-130814.pdf. Accessed 4 March 2016.
15. Ministry of Health Ghana Health Service. Two-year strategic plan for integrated neglected tropical diseases control in Ghana. 2007. Available at: http://www.moh-ghana.org/UploadFiles/Publications/Plan%20for%20Pro-Poor%20 Diseases120506091943.pdf. Accessed 4 March 2016.
16. Taylor MJ, Awadzi K, Basáñez MG, et al. Onchocerciasis control: vision for the future from a Ghanian perspective. Parasit Vectors 2009; 2:7.
17. Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98:231-49.
18. Awadzi K, Attah SK, Addy ET, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98:359-70.
19. Osei-Atweneboana MY, Eng JKL, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007; 369:2021-9.
20. Churcher TS, Pion SDS, Osei-Atweneboana MY, et al. Identifying sub-optimal responses to ivermectin in the treatment of river blindness. Proc Natl Acad Sci U S A 2009; 106:16716-21.
21. Turner HC, Osei-Atweneboana MY, Walker M, et al. The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study. PLoS Negl Trop Dis 2013; 7:e2452.
22. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. Geneva, Switzerland: WHO, 2012. Available at: http://www.who.int/neglected-diseases/NTD-RoadMap-2012-Fullversion.pdf. Accessed 4 March 2016.
23. Remme J, Ba O, Dadzie KY, Karam M. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. BullWorld Health Organ 1986; 64:667-81.
24. Diggle P, Heagerty P, Liang KY, Zeger SL. Analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press, 2013.
25. Lamberton PHL, Cheke RA, Winskill P, et al. Onchocerciasis transmission in Ghana: persistence under different control strategies and the role of the simuliid vectors. PLoS Negl Trop Dis 2015; 9:e0003688.
26. Lamberton PHL, Cheke RA, Walker M, et al. Onchocerciasis transmission in Ghana: biting and parous rates of host-seeking sibling species of the Simulium damnosum complex. Parasit Vectors 2014; 7:511.
27. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis 2011; 5:e998.
28. Pion SDS, Nana-Djeunga HC, Kamgno J, et al. Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-nave and multiply treated population from Cameroon. PLoS Negl Trop Dis 2013; 7:e2084.
29. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG. Uncertainity surrounding projections of the long-Term impact of ivermectin treatment on human onchocerciasis. PLoS Negl Trop Dis 2013; 7:e2169.
30. Turner HC, Walker M, Churcher TS, et al. Reaching the London Declaration on Neglected Tropical Diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis 2014; 59:923-32.
31. Taylor HR, Munoz B, Keyvan-Larijani E, Greene BM. Reliability of detection of microfilariae in skin snips in the diagnosis of onchocerciasis. Am J Trop Med Hyg 1989; 41:467-71.
32. Cupp E, Richards F, Lammie P, Eberhard M. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 2007; 370:1123.
33. Remme JHF, Amazigo U, Engels D, Barryson A, Yameogo L. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet 2007; 370:1123-4.
34. Eng JK, Prichard PK. A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated-And ivermectin-Treated patients. Mol Biochem Parasitol 2006; 142:193-202.
35. Bourguinat C, Pion SDS, Kamgno J, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis 2007; 1:e72.
36. Osei-Atweneboana MY, Boakye DA, Awadzi K, Gyapong JO, Prichard RK. Genotypic analysis of β-Tubulin in Onchocerca volvulus from communities and individuals showing poor parasitological response to ivermectin treatment. Int J Parasitol Drugs Drug Resist 2012; 2:20-8.
37. Walker M, Churcher TS, Basáñez MG. Models for measuring anthelmintic drug efficacy for parasitologists. Trends Parasitol 2014; 30:528-37.
38. Coffeng LE, Stolk WA, Hoerauf A, et al. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment. PLoS One 2014; 9:e115886.
39. Stolk WA, Walker M, Coffeng LE, Basáñez MG, de Vlas SJ. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. Parasit Vectors 2015; 8:552.
40. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG. Therapeutic efficacy and macrofilaricdal activity of doxycycline for the treatment of river blindness. Clin Infect Dis 2015; 60:1199-207.